The safety and tolerability profile of bilastine for chronic urticaria in children.
Bilastine
Children
Chronic urticaria
Second generation-antihistamine
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
06
2019
accepted:
04
10
2019
entrez:
30
10
2019
pubmed:
30
10
2019
medline:
30
10
2019
Statut:
epublish
Résumé
Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child's daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition. Therefore, the management of chronic urticaria must point to a complete control of symptoms, taking into account tolerability and the patient quality of life. The recently revised version of EAACI/GA In line with the recent guideline recommendation for the use of second generation H
Sections du résumé
BACKGROUND
BACKGROUND
Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child's daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition. Therefore, the management of chronic urticaria must point to a complete control of symptoms, taking into account tolerability and the patient quality of life.
REVIEW OF LITERATURE
METHODS
The recently revised version of EAACI/GA
CONCLUSIONS
CONCLUSIONS
In line with the recent guideline recommendation for the use of second generation H
Identifiants
pubmed: 31660121
doi: 10.1186/s13601-019-0294-3
pii: 294
pmc: PMC6806519
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
55Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Competing interestsDr. Papadopoulos reports Grants from Gerolymatos International SA and Capricare; personal fees from Hal, Novartis, Menarini/Faes Farma, Mylan/Meda, Nutricia, Sanofi, Biomay, AstraZeneca, GSK, MSD and Asit Biothech, outside the submitted work. Dr. Zuberbier reports grants or honoraria from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan, Leti, L’Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB. He also reports the following organizational affiliations: Committee member, WHO-Initiative “Allergic Rhinitis and its Impact on Asthma” (ARIA). Member of the Board, German Society for Allergy and Clinical Immunology (DGAKI). Head, European Centre for Allergy Research Foundation (ECARF). Secretary General, Global Allergy and Asthma European Network (GA2LEN). Member, Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).”
Références
Pharm Res. 2017 Dec;34(12):2720-2734
pubmed: 28971281
Biopharm Drug Dispos. 2004 Dec;25(9):373-87
pubmed: 15517550
Int Arch Allergy Immunol. 2011;155(4):367-78
pubmed: 21346367
J Dtsch Dermatol Ges. 2018 May;16(5):584-593
pubmed: 29750467
J Dermatol. 2017 Apr;44(4):375-385
pubmed: 27862227
Drug Saf. 2005;28(12):1101-18
pubmed: 16329713
Clin Exp Dermatol. 2010 Dec;35(8):869-73
pubmed: 20456386
Allergy Asthma Proc. 2018 Jul 20;39(4):299-304
pubmed: 29559031
Expert Opin Drug Saf. 2018 Sep;17(9):859-868
pubmed: 30032673
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Jul;19(7):790-795
pubmed: 28697833
Pediatr Allergy Immunol. 2016 Feb;27(1):55-61
pubmed: 26267219
J Psychopharmacol. 2011 Nov;25(11):1517-23
pubmed: 20855350
Eur J Pharm Sci. 2019 Feb 1;128:180-192
pubmed: 30468868
Pharmacol Ther. 2017 Oct;178:148-156
pubmed: 28457804
Allergol Int. 2017 Apr;66(2):317-325
pubmed: 27599913
Acta Derm Venereol. 2013 Mar 27;93(2):168-74
pubmed: 23053062
Eur J Pharmacol. 2018 Nov 5;838:107-111
pubmed: 30201377
J Clin Pharmacol. 2012 Jun;52(6):893-903
pubmed: 21642470
Clin Ther. 2000 May;22(5):613-21
pubmed: 10868558
Allergy. 2010 Apr;65(4):516-28
pubmed: 19860762
Ther Clin Risk Manag. 2016 Apr 13;12:585-97
pubmed: 27110120
Paediatr Respir Rev. 2018 Jan;25:1-2
pubmed: 28209474
Br J Clin Pharmacol. 2014 Nov;78(5):970-80
pubmed: 24833043
JAMA Dermatol. 2017 Dec 1;153(12):1236-1242
pubmed: 28973060
Pediatr Allergy Immunol. 2011 Feb;22(1 Pt 1):36-42
pubmed: 21261743
Chronobiol Int. 2016;33(7):883-92
pubmed: 27148770
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
Pediatr Allergy Immunol. 2016 Aug;27(5):493-8
pubmed: 26918853
Fundam Clin Pharmacol. 2001 Aug;15(4):269-77
pubmed: 11564134
Expert Opin Drug Saf. 2011 Sep;10(5):779-93
pubmed: 21831011
Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):820-828
pubmed: 29461615
Sleep. 2012 May 01;35(5):627-32
pubmed: 22547888
Curr Med Res Opin. 2017 Jan;33(1):129-136
pubmed: 27659218
Clin Pharmacokinet. 2009;48(8):543-54
pubmed: 19705924
Drug Chem Toxicol. 2012 Jun;35 Suppl 1:18-24
pubmed: 22616812
Pharmacol Rev. 2015 Jul;67(3):601-55
pubmed: 26084539
Int J Mol Sci. 2019 Jan 08;20(1):null
pubmed: 30626077
Clin Drug Investig. 2013 Sep;33(9):665-73
pubmed: 23873362
Ann Allergy. 1993 Aug;71(2):121-6
pubmed: 8346863
Sleep Med Rev. 2010 Jun;14(3):179-89
pubmed: 20093054
Immunol Rev. 2018 Mar;282(1):232-247
pubmed: 29431202
Allergy. 2009 Apr;64(4):605-12
pubmed: 19133920